MedTrace Logo

Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study

NCT02027480 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 685

Last updated 2015-12-24

No results posted yet for this study

Summary

The aim of this study is to develop and follow a cohort of human immunodeficiency virus (HIV)-infected adults who are starting HIV drugs at health facilities in Kenya. Blood and urine samples will be collected from all participants in order to establish a sample bank of samples in order to further the understanding of the levels of inflammatory biomarkers and coagulation biomarkers in African patients and the effect of taking HIV drugs on these biomarkers. This study will enroll and follow 685 men and women who are starting HIV drugs and collect blood and urine specimens from them at 4 study visits. These samples will be frozen and stored for future testing related to inflammatory and coagulation biomarkers.

Conditions

  • HIV (Human Immunodeficiency Virus)
  • AIDS (Acquired Immune Deficiency Syndrome)
  • Tuberculosis
  • Non-communicable Diseases (NCD)

Sponsors & Collaborators

Principal Investigators

  • Wafaa M El-Sadr, MD/MPH · ICAP-NY, Columbia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02027480 on ClinicalTrials.gov